The buyback includes up to 54.23 lakh fully paid-up equity shares with a face value of ₹1 each, offered at a price of ₹1,475 per share, payable in cash. The company stated that the Letter of Offer dated April 21, 2026, has been sent to eligible shareholders holding shares as of the record date of April 17, 2026.
The buyback period will commence on April 23, 2026, and conclude on April 29, 2026. The final date for the submission of completed tender forms and related documents to the registrar is April 29, 2026.
Also Read: Aurobindo Pharma receives FDA approval for cough medicine dextromethorphan ER
The settlement of bids by the clearing corporation/BSE is planned for May 7, 2026. The company had previously issued a public announcement regarding the buyback on April 8, 2026.
Buyback History
This marks Aurobindo Pharma’s first share buyback in nearly two years. In August 2024, the company announced a repurchase of 51.36 lakh equity shares at ₹1,460 per share. The drugmaker invested ₹750 crore for this buyback, which was also executed through the tender offer route.
Shares of Aurobindo Pharma Ltd closed at ₹1,387.05, an increase of ₹19.35, or 1.41%, on the BSE.
Also Read: Aurobindo Pharma unit expands MSD partnership, planning to invest $150-175 million in new facility
(Edited by : Jomy Jos Pullokaran)
First Published: Apr 21, 2026 4:45 PM IST
